Narrow Results

Higa Medical Systems to Market Cardiovascular System in Japan.

German Healthcare Company Sets Up Base in India.

Australian Food Company Enters Indian Market.

First Transgenic Farm to be Set Up in China.

Largest Medicine Chain Opens in Tianjin.

Monsanto Thailand Increases Efforts to Ease Concerns on GM Products.

An Overview — Molecular Diagnostics.

Interview with Mr Michael Tillmann, Managing Director, Roche Diagnostics, Asia Pacific.

Interview with Dr Paul Smit, Senior Vice President, Philips Medical Systems.

Developing a Complete Molecular Diagnostic Solution: Multiplex Analysis, High Performance, High Throughput and Automation.

Interview with QIAGEN World Leader in Molecular Diagnostics Solutions.

World Heart Day – At the Heart of Health

That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It

Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies.

Zuellig Pharma to Invest over $50 Million in Singapore-Based Innovation Centre.

Holmusk: Using Data to Improve Clinical Outcomes for Cardiovascular Disease in Singapore.

Singapore Eye Bank Sets Another Record in Local Cornea Donations in 2016.

Plasticell and King’s College London to Collaborate in Trials of Blood Platelet Substitute.

Merck Partners with University of California, San Diego (UCSD) to Fight Neglected Tropical Diseases.

Mundipharma Wins Approval for Antineoplastic Agent mundesine® as Treatment for Relapsed/Refractory Peripheral T-cell Lymphoma in Japan.

Asian Myeloma Network (AMN) Brings Clinical Trials to Cancer Patients in Asia and Provides Early Access to Effective Drugs.

APBN Interview with Professor Chng Wee Joo.

Cardiovascular diseases are the leading cause of death worldwide. The development of models to support clinical decision is of great importance in the management of these diseases. This work aims to improve the performance exhibited by risk assessment scores that are applied in the clinical practice. This methodology has three main phases: (i) representation of scores as a decision tree; (ii) optimization of the decision tree thresholds using data from recent clinical datasets; (iii) transformation of the optimized decision tree into a new score.

This approach was validated in a cardiovascular disease secondary prevention context, supported by a dataset provided by the Portuguese Society of Cardiology ($N=13902$). The respective performance was assessed using statistical metrics and was compared with GRACE score, the reference in Portuguese clinical practice. The new model originated a better balance between the sensitivity and specificity when compared with the GRACE, originating an accuracy improvement of approximately 22%.